Details of the Drug
General Information of Drug (ID: DM1BGQN)
Drug Name |
1-Methyl-1,2-dihydro-indazol-3-one
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
1006-19-5; 1-METHYL-1H-INDAZOL-3(2H)-ONE; 1H-Indazol-3-ol, 1-methyl-; 1,2-dihydro-1-methyl-3H-indazol-3-one; CHEMBL412905; 3H-Indazol-3-one, 1,2-dihydro-1-methyl-; 100922-97-2; 1-methyl-2,3-dihydro-1H-indazol-3-one; N-methylindazolone; 1,2-dihydro-1-methylindazol-3-one; NSC512755; 1-Methyl-1,2-dihydro-indazol-3-one; ACMC-1BUMW; AC1L6WKF; 1-methyl-3-hydroxyindazole; 1-methyl-2H-indazol-3-one; 1-Methyl-1H-indazole-3-ol; SCHEMBL2270654; SCHEMBL12998307; CTK0D9874; KS-00000SDI; ONNIFDMRZCMQQM-UHFFFAOYSA-N; MolPort-035-688-834
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 148.16 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.3 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 0 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||